Leadership changes at the US Food & Drug Administration put the agency at a key “inflection point” for the next phase of the implementation of the Oncology Center of Excellence – and may present an opportunity for the center to assume sign-off authority for biologics and devices along with drugs.
When it was stood up five years ago, the initial structure had OCE collaborating across centers within a framework that...








